Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use progr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Bhojwani, Deepa, Sposto, Richard, Shah, Nirali N., Rodriguez, Vilmarie, Yuan, Constance, Stetler-Stevenson, Maryalice, O’Brien, Maureen M., McNeer, Jennifer L., Quereshi, Amrana, Cabannes, Aurelie, Schlegel, Paul, Rossig, Claudia, Dalla-Pozza, Luciano, August, Keith, Alexander, Sarah, Bourquin, Jean-Pierre, Zwaan, Michel, Raetz, Elizabeth A., Loh, Mignon L., Rheingold, Susan R.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6438769/
https://ncbi.nlm.nih.gov/pubmed/30267011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0265-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados